What Cilazapril Treats: Main Uses and Benefits

Cilazapril is generally used in situations involving certain distressing symptoms across two major therapeutic domains, applied across domains where additional symptomatic support is needed. The medication is used to address hypertension and chronic heart failure. The therapeutic goal is to manage symptomatic patterns that are associated with physiological stress, and it may assist with maintaining functional stability.

The core indications involve conditions characterized by periods of heightened symptoms, such as Essential Hypertension and Congestive Heart Failure (CHF). The medication is commonly used to manage persistently elevated blood pressure readings or applied as adjunctive therapy when other treatments for heart failure, such as diuretics, require support. This supports the patient during difficult episodes by easing distress.

“The medication contributes to easing the overall symptom load through the reduction of pressure, which supports the patient's cardiovascular stability.”

Quick Fact: Support for Symptoms Related to Systemic Imbalance

Cilazapril generally supports the cardiovascular system and assists with maintaining stability when chronic symptoms are more noticeable. It is applied in addressing symptoms related to systemic imbalance by helping to moderate distressing manifestations. It also helps to ease circulatory congestion and functional strain associated with heart failure, which contributes to improved comfort during symptomatic periods.

Cilazapril eligibility is defined strictly by official regulatory labeling, outlining specific populations who must not use the medicine and those who require use under restricted conditions.

Absolute Contraindications

Cilazapril is contraindicated in the following populations:

• Patients with hypersensitivity to Cilazapril or any other ACE Inhibitor.
• Patients with a history of angioedema (swelling) related to previous ACE inhibitor therapy, or those with hereditary or idiopathic angioedema.
• Women in the second and third trimesters of pregnancy.
• Patients using Aliskiren who also have diabetes mellitus or renal impairment.
• Patients receiving a neprilysin inhibitor (e.g., sacubitril/valsartan); use is prohibited within 36 hours of the last dose.

️ Age and Conditional Restrictions

Use is also restricted and requires close supervision for patients with certain types of liver cirrhosis or those with bilateral renal artery stenosis.

Interactions with other medicines and products

The interaction profile of Cilazapril, an ACE inhibitor, is structured around official restrictions, specific timing rules, and documented changes in drug exposure or pharmacodynamic effects when co-administered with certain substances. All interaction information is aligned with regulatory labeling.

Official Interaction Statements

Timing and Context Constraints

Co-administration with Sacubitril/Valsartan requires a mandatory 36-hour washout period when switching between medications. The use of alcohol may result in a pharmacodynamic increase in the hypotensive effect. Cilazapril must be discontinued prior to commencing certain desensitization therapies to mitigate the documented risk of anaphylactoid reactions.

Cilazapril is an inactive pro-drug that undergoes hepatic hydrolysis to form its pharmacologically active metabolite, cilazaprilat. Cilazaprilat functions as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE). ACE, a metalloprotease, catalyzes the conversion of the inactive decapeptide angiotensin I to the potent vasoconstrictor, angiotensin II, within the Renin-Angiotensin-Aldosterone System (RAAS). By blocking ACE, cilazaprilat reduces the systemic circulating and local tissue concentrations of angiotensin II. The resulting decrease in angiotensin II leads to diminished stimulation of the AT1 receptors on vascular smooth muscle, causing a reduction in systemic vascular resistance. Furthermore, the suppression of angiotensin II reduces the production and secretion of aldosterone, which modulates the renal handling of sodium and water. The ultimate physiological consequence is the modulation of vascular tone and fluid homeostasis.

Cilazapril is administered orally (by mouth) and should be taken once daily at approximately the same time each day. The tablets must be swallowed whole with water and should not be chewed or crushed. Administration is permitted with or without food as food intake does not significantly affect its absorption.

Official Dosing and Administration Rules

For patients with renal impairment, the starting and maintenance doses must be adjusted based on the patient's creatinine clearance. In cases of missed dose, the official instruction is to take the dose as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped; a double dose must never be taken. Use in children and adolescents below 18 years of age is not recommended as safety and efficacy have not been established.

Research Evidence / Overview of Studies for Cilazapril

Evidence for Use in High Blood Pressure

The primary evidence for Cilazapril in the context of high blood pressure relies on short-term Randomized Controlled Trials (RCTs). These trials were primarily designed to quantify the effect on Systolic and Diastolic Blood Pressure readings. Research has explored not only the immediate change in these readings but also the research examined how blood pressure control was maintained over a full 24-hour period. Studies report how symptoms evolved in the observed populations, specifically patterns of blood pressure change when compared to control groups. Research has also monitored for changes in the structure of the heart, such as outcomes related to Left Ventricular Hypertrophy (LVH).

While studies provide a basis for understanding the medicine acts on blood pressure in the short-term, most of the dose-response trials are short in duration. This means that long-term effects are not fully established regarding the durability of the observed short-term outcomes reflecting daily functioning or activity level over many years. For evidence on long-term cardiovascular event patterns, research contributes to the broader evidence landscape based on the extensive body of research related to the ACE inhibitor class as a whole.

Evidence for Use in Chronic Heart Failure

The research for chronic heart failure was evaluated in long-term observational follow-up studies specific to the drug, combined with the comprehensive evidence from large-scale Randomized Controlled Trials evaluating the overall ACE inhibitor class. Studies have focused on measuring outcomes reflecting daily functioning or activity level, such as exercise tolerance and key measures like ejection fraction.

In these research scenarios, which often involve patients receiving the medicine as adjunctive therapy, findings describe patterns observed in the studies related to daily functioning and exercise performance. Systematic reviews of the ACE inhibitor class data show patterns related to outcomes related to physical discomfort and rates of hospitalization for heart failure when compared to control groups.

Evidence Gaps and Areas of Uncertainty

The research landscape for Cilazapril has several areas where information is still developing or where data is insufficient. A key limitation is the reliance on evidence generated for the entire ACE inhibitor class when discussing long-term cardiovascular events, as there is limited information for long-term outcomes specifically focused on Cilazapril.

Furthermore, the small sample sizes in the longest follow-up studies create a significant gap, meaning that results apply only to the populations studied and cannot be broadly generalized. Data for certain groups remain insufficient for groups such as children or pregnant individuals.

Key Studies & References

1. Vascace 1 mg Film-coated Tablets - Summary of Product Characteristics (SPC)
2. Drug Class Review on Angiotensin Converting Enzyme Inhibitors (ACEI Class Review)

Common questions about Cilazapril (FAQ)

Q: What are the serious side effects of Cilazapril?

Official regulatory documents indicate that serious side effects have been reported. These include angioedema, which is rapid swelling of the face, throat, or tongue, which can be life-threatening. Other serious risks include a significant drop in blood pressure and acute kidney injury. Less frequently, reports include changes in blood cells like decreased platelets, which official information classifies as Rare.

Q: Can I take Cilazapril with an NSAID like ibuprofen?

Using Cilazapril with non-steroidal anti-inflammatory drugs (NSAIDs) may reduce how effectively the medicine lowers blood pressure. Official warnings also state that this combination can increase the risk of developing kidney problems. Regulatory information suggests caution and conversation with a healthcare provider regarding the use of over-the-counter NSAIDs while taking this drug.

Q: Does Cilazapril interact with food?

Cilazapril can be taken either with or without food because food intake does not significantly change its absorption. However, since ACE inhibitors like Cilazapril can increase the amount of potassium in the body, official guidance recommends speaking with a healthcare professional before using any salt substitutes or supplements that contain potassium.

Q: Does this drug affect the way I drive or operate machinery?

Official product information notes that Cilazapril has been associated with side effects such as dizziness or light-headedness. This is especially true when starting the medicine or after a dose change. If these effects occur, driving or operating tools and machinery should be approached with caution.

Q: What should I do if I think I've taken too much Cilazapril (overdose)?

Official product information indicates that suspected overdose requires immediate contact with a healthcare practitioner, hospital emergency department, or a Poison Control Center. This guidance applies right away, even if there are no noticeable symptoms.

Q: What is the purpose of the 36-hour washout period with Sacubitril/Valsartan?

The 36-hour washout period is specified in regulatory information when switching between Cilazapril and medicines containing Sacubitril/Valsartan. This waiting period is necessary because combining the two classes of medicines is prohibited and greatly reduces the risk of developing angioedema, a potentially life-threatening form of swelling.

How to Store and Dispose of Cilazapril?

Proper Storage

Cilazapril tablets must be stored at room temperature (typically between 68 F and 77 F or 20 C and 25 C), away from excessive heat and moisture.

• Keep the medication in its original, tightly closed container.
• Do not store it in the bathroom or near a kitchen sink.
• Ensure it is kept out of the reach of children and pets.

Safe Disposal

When disposing of unused or expired cilazapril, do not flush it down a toilet or pour it down a drain unless specifically instructed to do so by a healthcare professional or an official medication take-back program.

• The best method is a drug take-back program, often available at pharmacies or police stations.
• If a take-back program is unavailable, mix the tablets with an unappealing substance like dirt or used coffee grounds, place the mixture in a sealed plastic bag, and throw it in the household trash.